Hjem
Universitetet i Bergen
Yaping Huas bilde

Yaping Hua

Postdoktor
Klinisk institutt 2
  • E-postyaping.hua@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • Vis forfatter(e) (2023). GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Frontiers in Immunology. 15 sider.
  • Vis forfatter(e) (2022). Proteasome‐mediated regulation of GATA2 expression and androgen receptor transcription in benign prostate epithelial cells. Biomedicines. 14 sider.
  • Vis forfatter(e) (2022). Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain. Frontiers in Pharmacology. 15 sider.
  • Vis forfatter(e) (2018). Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.
  • Vis forfatter(e) (2017). An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.
  • Vis forfatter(e) (2016). Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 sider.
  • Vis forfatter(e) (2013). Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Research. 7090-7100.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • Vis forfatter(e) (2017). Models of Tumor Progression in Prostate Cancer. 16 sider.
Poster
  • Vis forfatter(e) (2023). Regulation of Indoleamine dioxygenase 1 in human dendritic cells.
  • Vis forfatter(e) (2023). Potential of propionyl cinobufagin for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and neuroendocrine prostate cancer (NEPC).
  • Vis forfatter(e) (2023). In vitro Study of STAT3-inhibitors in Drug-Resistant Chronic Myeloid Leukemia (CML).
  • Vis forfatter(e) (2023). IDO-1 regulation in human dendritic cells.
  • Vis forfatter(e) (2022). Robust production of potent dendritic cells for cancer immunotherapy.
  • Vis forfatter(e) (2022). Robust and potent dendritic cells for cancer immunotherapy.
  • Vis forfatter(e) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
  • Vis forfatter(e) (2022). Novel STAT3 inhibitors targeting the STAT3 dimerization.
  • Vis forfatter(e) (2022). FLT3L and GM-CSF improve conventional dendritic cell viability and function.
  • Vis forfatter(e) (2020). Novel STAT3 inhibitors targeting STAT3 dimerization by binding to STAT3 SH2 domain.
  • Vis forfatter(e) (2013). Reactive oxygen species induce prostate cancer cells via activation of the IL6/STAT3 pathway. Abstract 304.
Faglig kapittel
  • Vis forfatter(e) (2022). Models of Tumor Progression in Prostate Cancer. 453-466. I:
    • Vis forfatter(e) (2022). Biomarkers of the Tumor Microenvironment. Springer.

Se fullstendig oversikt over publikasjoner i CRIStin.